Andrew was diagnosed with Multiple Myeloma over six years ago. Andrew went through five cycles of induction therapy, a stem cell transplant, and two years of maintenance therapy. He has been off all treatment since March of 2016. Andrew has been an avid cyclist for many years and credits his devotion to exercise with his ability to withstand his treatments with little in the way of serious side effects. Since retiring from full-time employment in 2015 Andrew has increased his time on the bike cycling for over 10,000 miles in three consecutive years. This is Andrew’s first participation in a fundraising event sponsored by the MMRF.
At Janssen Oncology, we’re shaping the future of cancer treatment. In the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.About Janssen Oncology
Click below to learn more about a treatment option for multiple myeloma. If you’re also interested in getting more information from Janssen, sign up for ongoing communications.Learn More